ストックスクリーナーアプリを入手
29.29
8.52%
2.30
前日終値:
$26.99
開ける：
$26.9
24時間の取引高:
397.32K
Relative Volume:
0.98
時価総額：
$1.42B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.16%
1か月 パフォーマンス:
+7.05%
6か月 パフォーマンス:
+176.84%
1年 パフォーマンス:
+42.88%
1日の値動き範囲:
$26.52
$29.69
1週間の範囲:
$26.52
$29.87
52週間の値動き範囲:
$5.485
$29.98
Oruka Therapeutics Inc Stock (ORKA) Company Profile
ORKA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
29.29 | 1.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Jefferies | Buy |
| 2025-10-27 | 開始されました | Guggenheim | Buy |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-10-11 | 開始されました | Stifel | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | Leerink Partners | Outperform |
| 2024-09-16 | 開始されました | TD Cowen | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2018-02-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 開始されました | Dawson James | Buy |
すべてを表示
Oruka Therapeutics Inc (ORKA) 最新ニュース
Does Oruka Therapeutics Inc. stock trade at a discount to peersJuly 2025 Volume & Weekly Market Pulse Alerts - newser.com
Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Can Oruka Therapeutics Inc. (HQ1) stock hit consensus price targetsWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock rise with strong economyRate Cut & High Accuracy Trade Signal Alerts - newser.com
Is Oruka Therapeutics Inc. stock attractive for income investorsQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-19 21:53:09 - newser.com
Can Oruka Therapeutics Inc. (HQ1) stock surprise with quarterly resultsPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Can Oruka Therapeutics Inc. stock sustain market leadershipEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Published on: 2025-11-19 17:15:05 - newser.com
Key metrics from Oruka Therapeutics Inc.’s quarterly dataPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Can momentum traders help lift Oruka Therapeutics Inc.July 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock sustain dividend payoutsWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock attract long term capital inflowsDividend Hike & Safe Capital Growth Tips - newser.com
Why Oruka Therapeutics Inc. (HQ1) stock is trending on social mediaQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliableJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Tools to monitor Oruka Therapeutics Inc. recovery probability2025 Macro Impact & AI Forecasted Stock Moves - newser.com
Is Oruka Therapeutics Inc. stock supported by strong cash flows2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Oruka Therapeutics Reports Q3 2025 Financial Results - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Research Analysts Issue Forecasts for ORKA FY2025 Earnings - Defense World
Oruka Therapeutics Inc (ORKA) 財務データ
Oruka Therapeutics Inc (ORKA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):